Market Place
Sourcing Support
Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US
16 May 2024 //
FDA
Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually
09 May 2024 //
ENDPTS
EC Expands Approval of BMS Reblozyl for LR-MDS
02 Apr 2024 //
BUSINESSWIRE
EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
02 Apr 2024 //
INDIANPHARMAPOST
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl
23 Feb 2024 //
BUSINESSWIRE
BMS Presents Efficacy and Safety Analysis of the Phase 3 Trial of Reblozyl
09 Dec 2023 //
BUSINESSWIRE
FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
05 Oct 2023 //
ONCLIVE
Roche`s SMA drug Evrysdi gets EU okay for pre-symptomatic babies
30 Aug 2023 //
GLOBENEWSWIRE
Bristol Myers Squibb has FDA approval for Reblozyl for anaemia
30 Aug 2023 //
PRESS RELEASE
U.S. FDA Approves BMS’s Reblozyl as First-Line Treatment of Anemia in Adults MDS
28 Aug 2023 //
BUSINESSWIRE
Bristol Myers details PhIII win in first-line test of Reblozyl
26 May 2023 //
ENDPTS
ASCO: BMS` $4B plan for Reblozyl takes shape—with one caveat
25 May 2023 //
FIERCE PHARMA
BMS to Present Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl
25 May 2023 //
BUSINESSWIRE
FDA Accepts for Priority Review sBLA and EMA Validates Application for Reblozyl
01 May 2023 //
PRESS RELEASE
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi
01 May 2023 //
BUSINESSWIRE
U.S. FDA Accepts for Priority Review Sbla & EMA Validates for Reblozyl
01 May 2023 //
BUSINESSWIRE
Bristol Myers Squibb bags third indication for Reblozyl in EU
04 Mar 2023 //
BUSINESSWIRE
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl for Adult
28 Jan 2023 //
BUSINESSWIRE
New therapy for anaemic myelodysplastic cancer patients
01 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
BMS scores a topline treat in Reblozyl phase 3 study
01 Nov 2022 //
FIERCEPHARMA
Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Approval in US
08 Jul 2022 //
FDA
BMS Withdraws sBLA for Reblozyl for NTD Beta Thalassemia
03 Jun 2022 //
BUSINESSWIRE
What To Expect From Bristol Myers Squibb Stock After Q1 Results?
28 Apr 2022 //
FORBES
BMS Announces New PDUFA Goal Date for Reblozyl sBLA
25 Mar 2022 //
BUSINESSWIRE
BMS and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl
11 Jun 2021 //
BUSINESSWIRE
Luspatercept is effective and well tolerated in patients with beta-thalassemia
11 Jun 2021 //
PRNEWSWIRE
Luspatercept is Efficacious and Well-Tolerated in Patients with ?-Thalassemia
11 Jun 2021 //
PRNEWSWIRE
BMS and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl
11 Jun 2021 //
BUSINESSWIRE
Luspatercept is effective and well tolerated in patients with beta-thalassemia
11 Jun 2021 //
PRNEWSWIRE
Luspatercept is Efficacious and Well-Tolerated in Patients with ?-Thalassemia
11 Jun 2021 //
PRNEWSWIRE
Health Canada Approves REBLOZYL® (luspatercept), New Class
16 Feb 2021 //
BIOSPACE
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment
16 Feb 2021 //
BUSINESSWIRE
Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations
04 Nov 2020 //
BUSINESSWIRE
Health Canada Approves REBLOZYL
29 Sep 2020 //
BIOSPACE
Health Canada Approves REBLOZYL® (luspatercept)
29 Sep 2020 //
BUSINESSWIRE
EC clears new class of anaemia therapy
29 Jun 2020 //
PHARMATIMES
European Commission Approves Reblozyl (luspatercept)
25 Jun 2020 //
BUSINESSWIRE
Acceleron Announces Presentations on REBLOZYL luspatercept-aamt at the 2020 ASCO
20 May 2020 //
BUSINESSWIRE
Reblozyl (luspatercept) Receives +ve CHMP Opinion for the Treatment of Adults
30 Apr 2020 //
BUSINESSWIRE
BMY`s, Acceleron rack up second OK for Reblozyl, onto blockbuster status
07 Apr 2020 //
PRESS RELEASE
Celgene`s Reblozyl (luspatercept-aamt) Receives Supplemental Approval in US
06 Apr 2020 //
FDA
New England Journal of Medicine Publishes Results from Pivotal Phase 3
26 Mar 2020 //
BUSINESSWIRE
NEJM Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl
26 Mar 2020 //
PRESS RELEASE
Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement
16 Dec 2019 //
FDA
Bristol and Acceleron Provide Update on FDA Advisory Committee for Reblozyl
06 Dec 2019 //
BUSINESS WIRE
Celgene`s Reblozyl faces FDA committee for myelodysplastic syndromes
03 Dec 2019 //
FIERCE PHARMA
Can Biohaven challenge the Allergan/AbbVie goliath in migraine?
03 Dec 2019 //
FIERCE PHARMA
Celgene`s Reblozyl (luspatercept-aamt) Receives Supplemental Approval in US
13 Nov 2019 //
FDA
FDA approves first therapy to treat patients with rare blood disorder
08 Nov 2019 //
PR NEWSWIRE
Another failed midstage asset for Acceleron sees shares fall
18 Sep 2019 //
FIERCE BIOTECH
Celgene wins approval for drug key to Bristol buyout
16 Aug 2019 //
BIOPHARMADIVE
Bristol-Myers` Celgene buy just chalked up another point in its favor
06 Jun 2019 //
FIERCE PHARMA
Celgene gains FDA review for blockbuster hopeful
05 Jun 2019 //
FIERCE BIOTECH
Celgene wraps up EU, U.S. filings for anemia drug luspatercept
27 Apr 2019 //
FIERCE BIOTECH
Celgene Submits Luspatercept MAA for MDS and Beta-Thalassemia to EMA
26 Apr 2019 //
BUSINESSWIRE
Celgene, Acceleron submit FDA application for billed blockbuster luspatercept
09 Apr 2019 //
ENDPTS
Celgene Corporation & Acceleron Announce Submission of Luspatercept BLA
05 Apr 2019 //
BUSINESSWIRE
